Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB-01
- Development stage
- Unknown
- Lead developer
- ABX
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PB-01 is a gallium-68 (^68Ga) labeled radiopharmaceutical developed by Primo Biotechnology for the diagnostic imaging of metastatic prostate cancer. As a radiotracer designed for use with PET/CT imaging technology, PB-01 specifically targets the Prostate Specific Membrane Antigen (PSMA), a cell-surface glycoprotein that is significantly overexpressed in prostate cancer cells. By binding to PSMA, the drug allows for the precise detection and monitoring of primary and metastatic lesions. PB-01 is the Taiwanese market equivalent of Radelumin, a diagnostic agent approved in Europe, and is being developed in collaboration with the German company ABX advanced biochemical compounds GmbH to improve precision oncology and patient staging in Taiwan.
- Other names
- 68Ga-labeled PSMA-targeting radiopharmaceutical68Ga-PSMA-11gallium Ga 68 gozetotide
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PB-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB-01.